LEXARIA BIOSCIENCE CORP. Revenue from Contract with Customer, Including Assessed Tax
LEXARIA BIOSCIENCE CORP. (LEXX) reported Revenue from Contract with Customer, Including Assessed Tax of $433.29 thousand for the 12-month period ending 2018-08-31, per its 10-K filed 2018-11-14.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2018-11-14
- LEXARIA BIOSCIENCE CORP. revenue from contract with customer, including assessed tax for fiscal 2018 was $433.29K, a 580.85% increase from fiscal 2017.
- LEXARIA BIOSCIENCE CORP. revenue from contract with customer, including assessed tax for fiscal 2017 was $63.64K, a 56.29% increase from fiscal 2016.
- LEXARIA BIOSCIENCE CORP. revenue from contract with customer, including assessed tax for fiscal 2016 was $40.72K.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|
| 2018-08-31 | $433.29K 10-K · filed 2018-11-14 |
| 2017-08-31 | $63.64K 10-K · filed 2018-11-14 |
| 2016-08-31 | $40.72K 10-K · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |